France’s THX Pharma (Euronext: ALTHX), formerly known as Theranexus and specializing in the treatment of rare neurological diseases, and Biocodex, an independent international pharmaceutical group, ...

In summary, if the conflict in the Middle East continues and oil prices stay elevated or move higher, this well could be the ...

Biocodex secures rights to Batten-1 and TX01 in agreement worth up to €173 million THX Pharma and Biocodex have entered a strategic licensing agreement covering three rare diseases, with Biocodex ...

GENTILLY, France--(BUSINESS WIRE)--THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing agreement to advance ...

GENTILLY, France, February 10, 2026--(BUSINESS WIRE)--THX Pharma (Theranexus) and Biocodex, an independent international pharmaceutical group, today announced the execution of a strategic licensing ...

Biocodex has acquired two licenses from THX Pharma to develop and commercialize Batten-1 worldwide and TX01 in the United States and Canada. The total deal value is up to €173 million, including a €12 ...

Batten-1 is being prepared for a Phase III trial scheduled to commence in 2026. Credit: Stock-Asso / Shutterstock.com. THX Pharma (Theranexus) and Biocodex have entered a strategic licensing agreement ...

The opinions expressed in this commentary represent those of the author. EdSource welcomes commentaries representing diverse points of view. If you would like to submit a commentary, please review our ...

A selection of content from Breakingviews. Explore a free 90-day trial of Breakingviews to read all stories. Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia ...

The primary uptrends in gold, silver, and the mining shares remain firmly in place, reinforcing the case for fresh highs into the second quarter. A speculative blow-off phase—carrying gold above ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Credit spreads are widening in software and private equity despite stable Treasuries. Read what could pressure the entire ...